Last reviewed · How we verify
Calcipotriol plus hydrocortisone ointment vehicle
Calcipotriol (a vitamin D analogue) reduces keratinocyte proliferation and promotes differentiation, while hydrocortisone provides anti-inflammatory effects to treat psoriasis.
Calcipotriol (a vitamin D analogue) reduces keratinocyte proliferation and promotes differentiation, while hydrocortisone provides anti-inflammatory effects to treat psoriasis. Used for Plaque psoriasis.
At a glance
| Generic name | Calcipotriol plus hydrocortisone ointment vehicle |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | Vitamin D analogue plus corticosteroid combination |
| Target | Vitamin D receptor (VDR); glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Calcipotriol binds to the vitamin D receptor on skin cells, normalizing their growth and maturation cycle while reducing inflammatory cytokine production. Hydrocortisone, a topical corticosteroid, suppresses local immune responses and inflammation. The combination provides synergistic efficacy for treating plaque psoriasis with reduced steroid burden compared to corticosteroid monotherapy.
Approved indications
- Plaque psoriasis
Common side effects
- Local skin irritation
- Pruritus
- Erythema
- Skin atrophy (from corticosteroid component)
Key clinical trials
- Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds (PHASE3)
- Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds (PHASE3)
- Vasoconstriction Trial With LEO 90100 Aerosol Foam (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: